The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Deflexifol (a novel formulation of 5FU): Phase 1 dose escalation study of infusional and bolus schedules after failure of standard treatment.
 
Philip R. Clingan
Employment - Southern Medical Day Care (I)
Stock and Other Ownership Interests - FivePhusion
Patents, Royalties, Other Intellectual Property - University of Wollongong
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Stephen P. Ackland
Consulting or Advisory Role - Baxalta
Research Funding - Bayer (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche
 
Marie Ranson
Stock and Other Ownership Interests - FivePhusion
Patents, Royalties, Other Intellectual Property - University of Wollongong
 
Daniel Brungs
No Relationships to Disclose
 
Morteza Aghmesheh
No Relationships to Disclose
 
Ali Tafreshi
No Relationships to Disclose
 
Madhu Bala Garg
No Relationships to Disclose
 
Suzanne Parker
Employment - Southern Medical Day Care
 
Anne Henderson
Employment - Southern Medical Day Care
 
Rebecca Jokela
No Relationships to Disclose
 
Paul L. De Souza
Honoraria - Janssen
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; Janssen; Pfizer
Research Funding - Multiple pharma companies
Expert Testimony - Janssen